Ruxolitinib for treatment of refractory hemophagocytic lymphohistiocytosis-Reference-Cited by-同舟云学术

Ruxolitinib for treatment of refractory hemophagocytic lymphohistiocytosis

Author:

Broglie Larisa¹²^ORCID,Pommert Lauren²³,Rao Sridhar⁴,Thakar Monica¹²,Phelan Rachel¹²,Margolis David¹²,Talano Julie¹²

Affiliation:

1. Division of Hematology, Oncology, and Blood and Marrow Transplant, Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI;

2. Children’s Hospital of Wisconsin, Milwaukee, WI;

3. Division of Hematology, Oncology, and Blood and Marrow Transplant, Department of Pediatrics, Children’s Hospital of Wisconsin, Milwaukee, WI; and

4. Blood Research Institute, Medical College of Wisconsin, Milwaukee, WI

Abstract

Key Points Optimal salvage therapy for refractory HLH is unknown. In our patient, ruxolitinib treatment led to clinical remission of refractory HLH.

Publisher

American Society of Hematology

Subject

Hematology

Link

Reference22 articles.

Cited by 110 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

2. Familial Lymphohistiocytosis;Reference Module in Life Sciences;2024

3. JAK Inhibitors in Cytokine Storm Syndromes;Advances in Experimental Medicine and Biology;2024

4. IL-6 Blockade in Cytokine Storm Syndromes;Advances in Experimental Medicine and Biology;2024